<?xml version="1.0" encoding="ISO-8859-1"?><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
<front>
<journal-meta>
<journal-id>0300-9041</journal-id>
<journal-title><![CDATA[Ginecología y obstetricia de México]]></journal-title>
<abbrev-journal-title><![CDATA[Ginecol. obstet. Méx.]]></abbrev-journal-title>
<issn>0300-9041</issn>
<publisher>
<publisher-name><![CDATA[Federación Mexicana de Colegios de Obstetricia y Ginecología A.C.]]></publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id>S0300-90412021000300006</article-id>
<article-id pub-id-type="doi">10.24245/gom.v88i3.5311</article-id>
<title-group>
<article-title xml:lang="es"><![CDATA[Efecto y tolerancia gastrointestinal de mioinositol vs metformina en el control metabólico y hormonal de pacientes con síndrome de ovario poliquístico]]></article-title>
<article-title xml:lang="en"><![CDATA[Gastrointestinal effect and tolerance of myoinositol vs metformin in the metabolic and hormonal control of patients with polycystic ovary syndrome]]></article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Aguilar-Mor]]></surname>
<given-names><![CDATA[María Elena]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Treviño-Báez]]></surname>
<given-names><![CDATA[Joaquín Darío]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Castañeda-Díaz]]></surname>
<given-names><![CDATA[Marisela]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[Martínez-Gaytán]]></surname>
<given-names><![CDATA[Victoria]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname><![CDATA[O-Pérez]]></surname>
<given-names><![CDATA[Luis Oswaldo de la]]></given-names>
</name>
<xref ref-type="aff" rid="Aff"/>
</contrib>
</contrib-group>
<aff id="Af1">
<institution><![CDATA[,Hospital de Ginecología y Obstetricia Dr. Ignacio Morones Prieto Unidad Médica de Alta Especialidad 23 ]]></institution>
<addr-line><![CDATA[Monterrey NL]]></addr-line>
<country>México</country>
</aff>
<aff id="Af2">
<institution><![CDATA[,Hospital de Ginecología y Obstetricia Dr. Ignacio Morones Prieto Unidad Médica de Alta Especialidad 23 ]]></institution>
<addr-line><![CDATA[Monterrey NL]]></addr-line>
<country>México</country>
</aff>
<aff id="Af3">
<institution><![CDATA[,Hospital de Ginecología y Obstetricia Dr. Ignacio Morones Prieto Unidad Médica de Alta Especialidad 23 ]]></institution>
<addr-line><![CDATA[Monterrey NL]]></addr-line>
<country>México</country>
</aff>
<aff id="Af4">
<institution><![CDATA[,Hospital de Ginecología y Obstetricia Dr. Ignacio Morones Prieto Unidad Médica de Alta Especialidad 23 ]]></institution>
<addr-line><![CDATA[Monterrey NL]]></addr-line>
<country>México</country>
</aff>
<pub-date pub-type="pub">
<day>00</day>
<month>00</month>
<year>2021</year>
</pub-date>
<pub-date pub-type="epub">
<day>00</day>
<month>00</month>
<year>2021</year>
</pub-date>
<volume>89</volume>
<numero>3</numero>
<fpage>222</fpage>
<lpage>231</lpage>
<copyright-statement/>
<copyright-year/>
<self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_arttext&amp;pid=S0300-90412021000300006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_abstract&amp;pid=S0300-90412021000300006&amp;lng=en&amp;nrm=iso"></self-uri><self-uri xlink:href="http://www.scielo.org.mx/scielo.php?script=sci_pdf&amp;pid=S0300-90412021000300006&amp;lng=en&amp;nrm=iso"></self-uri><abstract abstract-type="short" xml:lang="es"><p><![CDATA[Resumen  OBJETIVO:  Evaluar el efecto de las cápsulas de soft-gel de mioinositol en la reducción del índice de HOMA, el control metabólico y hormonal en pacientes con síndrome de ovario poliquístico versus metformina y la tolerabilidad gastrointestinal de ambos.  MATERIALES Y MÉTODOS:  Estudio clínico prospectivo, de etiqueta abierta, controlado no aleatorizado vs activo de referencia, con diseño de grupos paralelos efectuado en el servicio de Biología de la Reproducción Humana de la Unidad Médica de Alta Especialidad 23, IMSS, Monterrey NL, de agosto 2019 a octubre 2020, en pacientes con resistencia a la insulina asociada con síndrome de ovario poliquístico e infertilidad.  RESULTADOS:  Se estudiaron 83 pacientes: 33 que recibieron 600 mg de mioinositol en cápsulas soft-gel por vía oral cada 12 h y 50 que tomaron 850 mg de metformina cada 12 h durante 12 semanas. Completaron el estudio 75 pacientes. El grupo tratado con mioinositol tuvo una reducción del índice de HOMA de 1.49 ± 1.05 (con valor delta de cambio) versus el grupo tratado con metformina de 0.42 ± 0.40 (con igual valor delta de cambio). La diferencia entre ambos grupos fue estadísticamente significativa. Otros parámetros metabólicos y hormonales también tuvieron desenlaces favorables en ambos grupos, pero con una tendencia superior en el grupo de mioinositol.  CONCLUSIONES:  Se demostró la ventaja del tratamiento con mioinositol en la reducción del índice de HOMA y otros parámetros metabólicos y hormonales en pacientes con resistencia a la insulina asociada con síndrome de ovario poliquístico e infertilidad, con buena tolerabilidad gastrointestinal.]]></p></abstract>
<abstract abstract-type="short" xml:lang="en"><p><![CDATA[Abstract  OBJECTIVE:  To evaluate the effect of myoinositol soft-gel capsules on HOMA index reduction, metabolic and hormonal control in patients with polycystic ovary syndrome versus metformin and gastrointestinal tolerability of both.  MATERIALS AND METHODS:  Prospective, open-label, non-randomized vs active reference controlled clinical study with parallel group design performed in the Human Reproductive Biology service of the High Specialty Medical Unit 23, IMSS, Monterrey NL, from August 2019 to October 2020, in patients with insulin resistance associated with polycystic ovary syndrome and infertility.  RESULTS:  83 patients were studied: 33 who received 600 mg myoinositol soft-gel capsules orally every 12 h and 50 who took 850 mg metformin every 12 h for 12 weeks. Seventy-five patients completed the study. The myoinositol-treated group had a reduction in HOMA index of 1.49 ± 1.05 (with delta value of change) versus the metformin-treated group of 0.42 ± 0.40 (with equal delta value of change). The difference between the two groups was statistically significant. Other metabolic and hormonal parameters also had favorable outcomes in both groups, but with a superior trend in the myoinositol group.  CONCLUSIONS:  The advantage of myoinositol treatment in reducing the HOMA index and other metabolic and hormonal parameters in patients with insulin resistance associated with polycystic ovary syndrome and infertility was demonstrated, with good gastrointestinal tolerability.]]></p></abstract>
<kwd-group>
<kwd lng="es"><![CDATA[Mioinositol]]></kwd>
<kwd lng="es"><![CDATA[síndrome de ovario poliquístico]]></kwd>
<kwd lng="es"><![CDATA[metformina]]></kwd>
<kwd lng="es"><![CDATA[resistencia a la insulina]]></kwd>
<kwd lng="es"><![CDATA[infertilidad]]></kwd>
<kwd lng="en"><![CDATA[Myoinositol]]></kwd>
<kwd lng="en"><![CDATA[Polycystic ovary syndrome]]></kwd>
<kwd lng="en"><![CDATA[Metformin]]></kwd>
<kwd lng="en"><![CDATA[Insulin resistance]]></kwd>
<kwd lng="en"><![CDATA[Infertility]]></kwd>
</kwd-group>
</article-meta>
</front><back>
<ref-list>
<ref id="B1">
<label>1</label><nlm-citation citation-type="book">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Checa]]></surname>
<given-names><![CDATA[MA]]></given-names>
</name>
<name>
<surname><![CDATA[Espinós]]></surname>
<given-names><![CDATA[JJ]]></given-names>
</name>
<name>
<surname><![CDATA[Matorras]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
</person-group>
<source><![CDATA[Síndrome De Ovario Poliquístico]]></source>
<year>2012</year>
<edition>2</edition>
<publisher-loc><![CDATA[España ]]></publisher-loc>
<publisher-name><![CDATA[Médica Panamericana]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B2">
<label>2</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Teede]]></surname>
<given-names><![CDATA[HJ]]></given-names>
</name>
<name>
<surname><![CDATA[Misso]]></surname>
<given-names><![CDATA[ML]]></given-names>
</name>
<name>
<surname><![CDATA[Costello]]></surname>
<given-names><![CDATA[MF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome]]></article-title>
<source><![CDATA[Human Reproduction (Oxford, England)]]></source>
<year>2018</year>
<volume>33</volume>
<numero>9</numero>
<issue>9</issue>
<page-range>1602-18</page-range></nlm-citation>
</ref>
<ref id="B3">
<label>3</label><nlm-citation citation-type="book">
<collab>GPC</collab>
<source><![CDATA[Síndrome de Ovario Poliquístico]]></source>
<year>2013</year>
<page-range>1-50</page-range><publisher-loc><![CDATA[Ciudad de México ]]></publisher-loc>
<publisher-name><![CDATA[Instituto Mexicano del Seguro Social]]></publisher-name>
</nlm-citation>
</ref>
<ref id="B4">
<label>4</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Artini]]></surname>
<given-names><![CDATA[P]]></given-names>
</name>
<name>
<surname><![CDATA[Berardino]]></surname>
<given-names><![CDATA[O]]></given-names>
</name>
<name>
<surname><![CDATA[Papini]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Endocrine and clinical effects of myo-inositol administration in polycystic ovary syndrome. A randomized study]]></article-title>
<source><![CDATA[Gynecol Endocrinol]]></source>
<year>2013</year>
<volume>29</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>375-9</page-range></nlm-citation>
</ref>
<ref id="B5">
<label>5</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Fruzzetti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Perini]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
<name>
<surname><![CDATA[Russo]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of two insulin sensitizers, metformin and myo-inositol, in women with polycystic ovary syndrome (PCOS)]]></article-title>
<source><![CDATA[Gynecol Endocrinol]]></source>
<year>2017</year>
<volume>33</volume>
<numero>1</numero>
<issue>1</issue>
<page-range>39-42</page-range></nlm-citation>
</ref>
<ref id="B6">
<label>6</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Pkhaladze]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Barbakadze]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Kvashilava]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myo-inositol in the Treatment of Teenagers Affected by PCOS]]></article-title>
<source><![CDATA[Int J Endocrinol]]></source>
<year>2016</year>
<volume>2016</volume>
</nlm-citation>
</ref>
<ref id="B7">
<label>7</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Magendzon]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Anovulación y disfunción ovulatoria e infertilidad]]></article-title>
<source><![CDATA[Rev Med Clin Condes]]></source>
<year>2010</year>
<volume>21</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>377-86</page-range></nlm-citation>
</ref>
<ref id="B8">
<label>8</label><nlm-citation citation-type="journal">
<collab>Sociedad Española de Ginecología Obstetricia</collab>
<article-title xml:lang=""><![CDATA[Guía de asistencia práctica. Estudio y tratamiento de la anovulación en el síndrome de ovarios poliquísticos]]></article-title>
<source><![CDATA[Prog Obstet Ginecol]]></source>
<year>2017</year>
<volume>60</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>505-16</page-range></nlm-citation>
</ref>
<ref id="B9">
<label>9</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Papaleo]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
<name>
<surname><![CDATA[Unfer]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Baillargeon]]></surname>
<given-names><![CDATA[JP]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myo-inositol in patients with polycystic ovary syndrome: A novel method for ovulation induction]]></article-title>
<source><![CDATA[Gynecol Endocrinol]]></source>
<year>2007</year>
<volume>23</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>700-3</page-range></nlm-citation>
</ref>
<ref id="B10">
<label>10</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Showell]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Mackenzie]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Jordan]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inositol for subfertile women with polycystic ovary syndrome]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2018</year>
<volume>12</volume>
<numero>12</numero>
<issue>12</issue>
<page-range>CD012378</page-range></nlm-citation>
</ref>
<ref id="B11">
<label>11</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Tso]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Costello]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Albuquerque]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Metformin treatment before and during IVF or ICSI in women with polycystic ovary syndrome]]></article-title>
<source><![CDATA[Cochrane Database Syst Rev]]></source>
<year>2014</year>
<volume>2014</volume>
<numero>11</numero>
<issue>11</issue>
</nlm-citation>
</ref>
<ref id="B12">
<label>12</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Unfer]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Facchinetti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Orrú]]></surname>
<given-names><![CDATA[B]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myo-inositol effects in women with PCOS a meta-analysis of randomized controlled trials]]></article-title>
<source><![CDATA[Endocr Connect]]></source>
<year>2017</year>
<volume>6</volume>
<numero>8</numero>
<issue>8</issue>
<page-range>647-58</page-range></nlm-citation>
</ref>
<ref id="B13">
<label>13</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Agrawal]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
<name>
<surname><![CDATA[Mahey]]></surname>
<given-names><![CDATA[R]]></given-names>
</name>
<name>
<surname><![CDATA[Kachhawa]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of metformin plus myoinositol vs metformin alone in PCOS women undergoing ovulation induction cycles: randomized controlled trial]]></article-title>
<source><![CDATA[Gynecol Endocrinol]]></source>
<year>2019</year>
<volume>35</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>511-4</page-range></nlm-citation>
</ref>
<ref id="B14">
<label>14</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Özay]]></surname>
<given-names><![CDATA[ÖE]]></given-names>
</name>
<name>
<surname><![CDATA[Özay]]></surname>
<given-names><![CDATA[AC]]></given-names>
</name>
<name>
<surname><![CDATA[Çagliyan]]></surname>
<given-names><![CDATA[E]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myo-inositol administration positively effects ovulation induction and intrauterine insemination in patients with polycystic ovary syndrome: a prospective, controlled, randomized trial]]></article-title>
<source><![CDATA[Gynecol Endocrinol]]></source>
<year>2017</year>
<volume>33</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>524-8</page-range></nlm-citation>
</ref>
<ref id="B15">
<label>15</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Nas]]></surname>
<given-names><![CDATA[K]]></given-names>
</name>
<name>
<surname><![CDATA[Túú]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[A comparative study between myo-inositol and metformin in the treatment of insulin-resistant women]]></article-title>
<source><![CDATA[Eur Rev Med Pharmacol Sci]]></source>
<year>2017</year>
<volume>21</volume>
<numero>^s2</numero>
<issue>^s2</issue>
<supplement>2</supplement>
<page-range>77-82</page-range></nlm-citation>
</ref>
<ref id="B16">
<label>16</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Baños]]></surname>
<given-names><![CDATA[N]]></given-names>
</name>
<name>
<surname><![CDATA[de lal Rosa]]></surname>
<given-names><![CDATA[L]]></given-names>
</name>
<name>
<surname><![CDATA[Vallejo]]></surname>
<given-names><![CDATA[CF]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Eficacia del Inositol en las mujeres con Síndrome del Ovario Poliquístico y deseo genésico: Revisión sistemática y metaanálisis]]></article-title>
<source><![CDATA[Rev Iberoam Fert Rep Hum]]></source>
<year>2012</year>
<volume>29</volume>
<numero>4</numero>
<issue>4</issue>
<page-range>129-37</page-range></nlm-citation>
</ref>
<ref id="B17">
<label>17</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Kamenov]]></surname>
<given-names><![CDATA[Z]]></given-names>
</name>
<name>
<surname><![CDATA[Kolarov]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Gateva]]></surname>
<given-names><![CDATA[A]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Ovulation induction with myo-inositol alone and in combination with clomiphene citrate in polycystic ovarian syndrome patients with insulin resistance]]></article-title>
<source><![CDATA[Gynecol Endocrinol]]></source>
<year>2015</year>
<volume>31</volume>
<numero>2</numero>
<issue>2</issue>
<page-range>131-5</page-range></nlm-citation>
</ref>
<ref id="B18">
<label>18</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carlomagno]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[Unfer]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myo-inositol in the treatment of premenstrual dysphoric disorder]]></article-title>
<source><![CDATA[Hum Psychopharmacol]]></source>
<year>2011</year>
<volume>26</volume>
<numero>7</numero>
<issue>7</issue>
<page-range>526-30</page-range></nlm-citation>
</ref>
<ref id="B19">
<label>19</label><nlm-citation citation-type="journal">
<collab>Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group</collab>
<article-title xml:lang=""><![CDATA[Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome]]></article-title>
<source><![CDATA[Fertil Steril]]></source>
<year>2004</year>
<volume>81</volume>
<page-range>19-25</page-range></nlm-citation>
</ref>
<ref id="B20">
<label>20</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Carlomagno]]></surname>
<given-names><![CDATA[G]]></given-names>
</name>
<name>
<surname><![CDATA[de Grazia]]></surname>
<given-names><![CDATA[S]]></given-names>
</name>
<name>
<surname><![CDATA[Unfer]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Myo-inositol in a new pharmaceutical form: a step forward to a broader clinical use]]></article-title>
<source><![CDATA[Expert Opin Drug Deliv]]></source>
<year>2012</year>
<volume>9</volume>
<numero>3</numero>
<issue>3</issue>
<page-range>267-71</page-range></nlm-citation>
</ref>
<ref id="B21">
<label>21</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Shokrpour]]></surname>
<given-names><![CDATA[M]]></given-names>
</name>
<name>
<surname><![CDATA[Foroozanfard]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Ebrahimi]]></surname>
<given-names><![CDATA[FA]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Comparison of myo-inositol and metformin on glycemic control, lipid profiles, and gene expression related to insulin and lipid metabolism in women with polycystic ovary syndrome: a randomized controlled clinical trial]]></article-title>
<source><![CDATA[Gynecol Endocrinol]]></source>
<year>2019</year>
<volume>35</volume>
<numero>5</numero>
<issue>5</issue>
<page-range>406-11</page-range></nlm-citation>
</ref>
<ref id="B22">
<label>22</label><nlm-citation citation-type="journal">
<person-group person-group-type="author">
<name>
<surname><![CDATA[Facchinetti]]></surname>
<given-names><![CDATA[F]]></given-names>
</name>
<name>
<surname><![CDATA[Unfer]]></surname>
<given-names><![CDATA[V]]></given-names>
</name>
<name>
<surname><![CDATA[Dewailly]]></surname>
<given-names><![CDATA[D]]></given-names>
</name>
</person-group>
<article-title xml:lang=""><![CDATA[Inositols in Polycystic Ovary Syndrome An Overview on the Advances]]></article-title>
<source><![CDATA[Trends Endocrinol Metab]]></source>
<year>2020</year>
<volume>31</volume>
<numero>6</numero>
<issue>6</issue>
<page-range>435-47</page-range></nlm-citation>
</ref>
</ref-list>
</back>
</article>
